cas 115619-00-6|| where to buy 1-Ethyl-4-(4-nitrophenyl)piperazine

Название продукции:1-Ethyl-4-(4-nitrophenyl)piperazine

IUPAC Name:1-ethyl-4-(4-nitrophenyl)piperazine

Упаковочная единица	Доступно для заказа	Цена ($)
CM120162-5g	in stock	Źů
CM120162-10g	in stock	ǪĲĲ
CM120162-25g	in stock	ľŹů
CM120162-100g	1-2 Weeks	ŗƥŹ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 115619-00-6 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:115619-00-6; Молекулярная формула:C12H17N3O2; Точка плавления:-; Smiles-код:O=[N+](C1=CC=C(N2CCN(CC)CC2)C=C1)[O-]; Плотность:

: Номер в каталоге:CM120162; Молекулярная масса:235.29; Точка кипения:; Номер Mdl:MFCD00614372; Хранение:Store at room temperature.

: Piperazines; Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.

: Infigratinib; Sept. 06, 2023, positive feedback from the U.S. FDA and the EU EMA on key elements of the trial design for PROPEL3, its pivotal Phase 3 study of infigratinib in children with achondroplasia.
Achondroplasia is the most common cause of disproportionate short stature, affecting approximately 55,000 people in the United States and European Union, including up to 10,000 children and adolescents with open growth plates. Achondroplasia impacts overall health and quality of life, leading to medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis. The condition is uniformly caused by an activating mutation in FGFR3.
Infigratinib is an oral small molecule designed to inhibit FGFR3 and target achondroplasia at its source. It is incredibly exciting that infigratinib has the potential to become the first effective oral treatment option to improve growth, enhance functionality and decrease complications.